

[54] **ENRICHED PLASMA DERIVATIVE FOR
ENHANCEMENT OF WOUND CLOSURE
AND COVERAGE**

[75] Inventor: **Michael Stroetmann, Münster, Fed.
Rep. of Germany**

[73] Assignee: **Serapharm Michael Stroetmann,
Münster, Fed. Rep. of Germany**

[21] Appl. No.: **385,665**

[22] Filed: **Jun. 7, 1982**

[30] **Foreign Application Priority Data**

Jun. 25, 1981 [DE] Fed. Rep. of Germany 3124962

[51] Int. Cl.³ **A61K 9/14; A61K 35/14;
A61K 37/00**

[52] U.S. Cl. **424/46; 424/45;
424/101; 424/177**

[58] Field of Search **424/101, 177, 46, 45**

[56] **References Cited**

U.S. PATENT DOCUMENTS

4,298,598 11/1981 Schwarz et al. 424/101
4,362,567 12/1982 Schwarz et al. 424/101

OTHER PUBLICATIONS

Schwarz et al.—Chem. Abst., vol. 94 (1981), p. 36318q.
Schwarz et al.—Chem. Abst., vol. 94, (1981), p. 36384h.
McKendrick et al.—Chem. Abst., vol. 76 (1972), p.
17809n.

Primary Examiner—Sam Rosen

Attorney, Agent, or Firm—Gordon W. Hueschen

[57] **ABSTRACT**

A sprayable preparation for accelerated hemostasis and optimized biochemical control of wound closure contains a powdery mixture of 15 to 60% by weight of thrombin, 5 to 80% by weight of a desiccating and stabilizing agent, viz., albumin, globulin and/or fibrinogen, and 1 to 10% by weight of a fibrinolysis inhibitor. The powdery mixture is suspended in a low-boiling, anhydrous solvent, which is used as a propellant. For effective wound closure and coverage, a spray jet of this suspension is directed onto the wound under evaporation of the solvent so that substantially only the dry, solid powdery mixture reaches the wound. This method of application by spraying is also disclosed.

20 Claims, No Drawings